Literature DB >> 2120086

Follicular development and oocyte maturation after stimulation with gonadotropins versus leuprolide acetate/gonadotropins during in vitro fertilization.

K H Thanki1, C L Schmidt.   

Abstract

Follicular development and oocyte maturation were compared in 22 patients stimulated with human menopausal gonadotropins/human chorionic gonadotropin (hCG, group I) and in 52 women also treated with the gonadotropin-releasing hormone agonist (GnRH-a) leuprolide acetate (LA, group II). Suppression of endogenous leutinizing hormone (LH) surges by LA allowed delayed hCG administration, resulting in higher peripheral estradiol levels, more retrieved oocyte cumulus corona complexes, and greater numbers of cryopreserved embryos. Reduction in spontaneous LH surges in the GnRH-a cycles may have allowed time for larger follicular fluid (FF) volume accumulation during all phases of oocyte cumulus corona complex maturation, restoring synchrony between FF volume and oocyte cumulus corona complex maturity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120086     DOI: 10.1016/s0015-0282(16)53825-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Treatment variables in relation to oocyte maturation: lessons from a clinical micromanipulation-assisted in vitro fertilization program.

Authors:  O M Avrech; G A Goldman; O Rufas; A Stein; S Amit; I Yoles; H Pinkas; B Fisch
Journal:  J Assist Reprod Genet       Date:  1997-07       Impact factor: 3.412

2.  Prediction of nuclear maturity from cumulus-coronal morphology: influence of embryologist experience.

Authors:  D G Hammitt; C H Syrop; B J Van Voorhis; D L Walker; T M Miller; K M Barud; C C Hood
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

Review 3.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.